The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
We are pleased to present below all posts archived in 'January, 2017'. If you still can't find what you are looking for, try using the search box.
Harwell, UK - The Electrospinning Company, announces that it has secured a £650,000 investment to establish itself as the leading provider of clinical-grade electrospun biomaterials to the medical device industry. Funding has come from a network of UK angel investors, including Angels 5K, LBA, Minerva, Wroxall, Angels in MedCity and OION, as well as from the Rainbow Seed Fund.
Read the rest of entry »
Oxford, UK & Bagsværd, Denmark - University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford.
Alexandria & San Jose, USA and Oxford, UK – Oxford Finance LLC, an industry-leading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $10 million senior secured term loan with Oxford BioTherapeutics (“OBT”), an international, clinical-stage biotechnology company focused on developing antibody-based therapies to treat cancer.
London, UK - Tests including an ultrasonic hologram and treatments for serious conditions, such as hospital superbugs, are the latest projects to win a share of Government funding. Sixty seven projects will win a share of £26 million funding available through Biomedical Catalyst 2016, which is run by Innovate UK and the Medical Research Council, and aims to develop innovative healthcare technologies and processes.
Cambridge, UK – Cresset, innovative provider of software and contract research services for small molecule discovery and design, is pleased to announce a corporate rebrand, reflecting a new structure for this growing business.
Gosport, UK - Wickham Laboratories Ltd is pleased to provide the results of our case study on the bioburden of the new polymer £5 note.
Cambridge, UK - PiR was delighted to host senior representatives from the life sciences community, together with the industry trade press, at its CEO Breakfast Forum, which took place at the Chesterford Research Park, Cambridge, United Kingdom on 17 January.
Chipping Warden, UK - GFC Diagnostics has been awarded one of the three Longitude Prize Discovery Awards awarded to UK organisations for the company’s ground-breaking development of a test which successfully detects antibiotic resistant bacteria, including the superbug MRSA, within 30 minutes.
San Diego, USA & Palma, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced that the first patient has been enrolled in the Phase IIb “CaLIPSO Study” clinical trial of lead candidate, SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).
Oxford, UK – Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile infection (‘CDI’), today announces the appointment of Dr David Roblin as Chief Operating Officer (‘COO’) and President of Research and Development.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, email@example.com, and we will post.